Logo image of NRSN

NEUROSENSE THERAPEUTICS LTD (NRSN) Stock Fundamental Analysis

NASDAQ:NRSN - Nasdaq - IL0011809592 - Common Stock - Currency: USD

2.03  0 (0%)

After market: 2.0497 +0.02 (+0.97%)

Fundamental Rating

0

NRSN gets a fundamental rating of 0 out of 10. The analysis compared the fundamentals against 553 industry peers in the Biotechnology industry. NRSN may be in some trouble as it scores bad on both profitability and health. NRSN does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year NRSN has reported negative net income.
In the past 5 years NRSN always reported negative net income.
In the past 5 years NRSN always reported negative operating cash flow.
NRSN Yearly Net Income VS EBIT VS OCF VS FCFNRSN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M -10M

1.2 Ratios

The Return On Assets of NRSN (-1061.28%) is worse than 97.65% of its industry peers.
Industry RankSector Rank
ROA -1061.28%
ROE N/A
ROIC N/A
ROA(3y)-233.27%
ROA(5y)-219.6%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NRSN Yearly ROA, ROE, ROICNRSN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 1K 2K 3K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for NRSN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NRSN Yearly Profit, Operating, Gross MarginsNRSN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

0

2. Health

2.1 Basic Checks

NRSN has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, NRSN has more shares outstanding
NRSN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
NRSN Yearly Shares OutstandingNRSN Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
NRSN Yearly Total Debt VS Total AssetsNRSN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

NRSN has an Altman-Z score of -79.19. This is a bad value and indicates that NRSN is not financially healthy and even has some risk of bankruptcy.
NRSN has a worse Altman-Z score (-79.19) than 95.66% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -79.19
ROIC/WACCN/A
WACCN/A
NRSN Yearly LT Debt VS Equity VS FCFNRSN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 5M -5M -10M

2.3 Liquidity

A Current Ratio of 0.21 indicates that NRSN may have some problems paying its short term obligations.
NRSN has a worse Current ratio (0.21) than 95.48% of its industry peers.
A Quick Ratio of 0.21 indicates that NRSN may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.21, NRSN is doing worse than 95.30% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.21
Quick Ratio 0.21
NRSN Yearly Current Assets VS Current LiabilitesNRSN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for NRSN have decreased strongly by -48.86% in the last year.
EPS 1Y (TTM)-48.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.5%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

NRSN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 50.66% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y4.93%
EPS Next 2Y18.4%
EPS Next 3Y17.04%
EPS Next 5Y50.66%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NRSN Yearly Revenue VS EstimatesNRSN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
NRSN Yearly EPS VS EstimatesNRSN Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 4 6 8 10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NRSN. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NRSN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NRSN Price Earnings VS Forward Price EarningsNRSN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NRSN Per share dataNRSN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.1 -0.2 -0.3 -0.4 -0.5

4.3 Compensation for Growth

A more expensive valuation may be justified as NRSN's earnings are expected to grow with 17.04% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.4%
EPS Next 3Y17.04%

More info and screens

0

5. Dividend

5.1 Amount

NRSN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEUROSENSE THERAPEUTICS LTD

NASDAQ:NRSN (7/28/2025, 8:00:02 PM)

After market: 2.0497 +0.02 (+0.97%)

2.03

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)07-23 2025-07-23
Earnings (Next)N/A N/A
Inst Owners0.81%
Inst Owner ChangeN/A
Ins Owners21.38%
Ins Owner ChangeN/A
Market Cap48.70M
Analysts80
Price Target14.28 (603.45%)
Short Float %2.38%
Short Ratio1.2
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)61.4%
Min EPS beat(2)32.6%
Max EPS beat(2)90.2%
EPS beat(4)3
Avg EPS beat(4)19.24%
Min EPS beat(4)-67.38%
Max EPS beat(4)90.2%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)30.23%
PT rev (3m)86.67%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)15.41%
EPS NY rev (3m)0.33%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.54
EYN/A
EPS(NY)-0.51
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS-0.12
TBVpS-0.12
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -1061.28%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-233.27%
ROA(5y)-219.6%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.21
Quick Ratio 0.21
Altman-Z -79.19
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)76.5%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-48.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.5%
EPS Next Y4.93%
EPS Next 2Y18.4%
EPS Next 3Y17.04%
EPS Next 5Y50.66%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y24.12%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-20.94%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-21.32%
OCF growth 3YN/A
OCF growth 5YN/A